Applied Molecular Transport Inc. (NASDAQ: AMTI) was founded in 2016 and is headquartered in South San Francisco, California, USA. It has 49 full-time employees. It is a clinical-stage biopharmaceutical company that uses the company’s proprietary technology platform to design And develop a series of new oral biological products candidate products to treat autoimmune diseases, inflammatory diseases, metabolic diseases and other diseases.
Applied Molecular Transport (AMTI):
Applied Molecular Therapeutics is committed to developing novel oral biological therapies to treat severe autoimmune, metabolic and inflammatory diseases. To achieve this goal, the company is using its proprietary technology platform to develop oral therapies that use naturally occurring transport and targeting mechanisms to cross the protective barrier of the intestinal epithelium (IE). Once the IE is passed, the therapist can gain privileged access to the immune system, which provides the potential for the therapeutic payload to act directly at the origin of immune disorders and restore immune homeostasis.
Applied Molecular Therapeutics’ proprietary technology platform enables it to utilize existing natural cellular transport pathways to facilitate the active transport of therapeutic payloads through the IE barrier. Active transport is an effective mechanism that uses the cell’s own mechanism to transport on the IE barrier.
In addition, by traversing the protective IE, AMT found a way to access the hepatic hilar system and downstream systemic circulation with privileges, opening the door to the treatment of liver and metabolic diseases and other diseases. With this privilege, the goal of AMT is to develop new and transformative treatment methods that provide patients with better efficacy and tolerability than today’s treatment methods.
Enjoying the privilege of the immune system and hepatic portal targets laid the foundation for AMT to change the paradigm of treatment strategies across multiple disease areas. Applied Molecular Therapeutics is developing patient-friendly oral biologics candidates in the form of tablets and capsules. These formulations are designed to target local gastrointestinal (GI) tissues or enter the systemic circulatory system to precisely address the biological problems associated with the disease .
Applied Molecular Therapeutics is building an oral drug candidate product portfolio including oral drug candidate AMT-101 and oral GI selective interleukin 10 (IL-10) based on the company’s technology platform. The product has been completed in patients with ulcerative colitis Phase Ib clinical trial (UC). The company further plans to initiate Phase II clinical trials of AMT-101 in UC and related inflammatory indications.
Applied Molecular Therapeutics’ technology platform enables the company to design and develop a variety of oral biological therapies, such as peptides, proteins, full-length antibodies, antibody fragments, and RNA therapeutics. Compared with existing drugs in the market and development stage, they have potential The significant advantages.
Applied Molecular Therapeutics financing:
- On October 1, 2018, in Series B financing, Applied Molecular Therapeutics received a joint investment of US$31 million from Founders Fund and EPIQ Capital Group.
- On October 1, 2019, in Series C financing, Applied Molecular Therapeutics received US$41.9 million in investment from Founders Fund and EPIQ Capital Group.
Applied Molecular Transport (AMTI) investment:
Applied Molecular Transport Inc. (NASDAQ: AMTI) was listed on NASDAQ at IPO on 6/5/2020, with an issue price of $14.00, issuing 10 million shares, raising US$140 million, BofA Securities/Jefferies/ SVB Leerink Underwriting.